Greece's single public health insurer. It pays for medicines, tests and care for the insured, dispenses high-cost medicines through its own pharmacies, and runs the electronic pre-approval system through which medicines can be paid for case by case.
The Εθνικός Οργανισμός Παροχής Υπηρεσιών Υγείας is the single insurer that the OECD and European Commission's 2025 profile describes as reimbursing laboratories, diagnostic centres and private hospitals without strict preconditions or links to quality. Law 4931/2022 (Government Gazette A 94, 13 May 2022), as published by the organisation, sets up in it a committee to negotiate the prices it pays for health services, devices and materials, introduces horizon scanning of medicines in its Pharmaceutical Directorate, and lets its board, after the opinion of the national committee for the evaluation and reimbursement of medicines, approve in exceptional cases a medicine that is not on the reimbursed list for one patient's course of treatment. The same law opens the electronic pre-approval system, in which reviewing doctors decide whether a medicine needs to be reimbursed, to private doctors, with at least five reviewers in each listed specialty, medical oncology and radiotherapy among them.
High-cost medicines are collected from the organisation's own pharmacies; where none works locally, its page says they can be ordered through dispatch points, with a maximum estimated wait of 10 to 15 days from handing in the prescription. The page does not say which cancer medicines are on the high-cost list. The OECD profile records that Greece's main tools to control spending on cancer medicines are price negotiations, rebates and clawbacks, and that public hospitals are paid through a hybrid of diagnosis-related groups and retrospective budget payments.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/